Close

UPS Completes Acquisition of MNX Global Logistics

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

UPS announced that it has completed the acquisition of MNX Global Logistics (MNX), a global time-critical logistics provider. The acquisition closed on Nov. 2, 2023, following all required regulatory approvals.

The acquisition of MNX expands UPS’s capabilities of time-critical logistics, especially for healthcare customers in the US, Europe and Asia. MNX has a strong track record in providing reliable and timely delivery of critical goods. The company’s expertise in transporting radiopharmaceuticals and temperature-sensitive products will help UPS Healthcare and its clinical trial logistics subsidiary, Marken, meet the growing demand for these services in the healthcare industry. With MNX’s additional expertise, UPS will continue to offer industry-leading global service to customers who need time-critical, temperature-sensitive logistics solutions.

The acquisition of MNX is part of UPS’s ongoing strategy to invest in new technologies and capabilities, providing customers with the most reliable and efficient logistics solutions possible.

 

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back